# A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients

> **NCT01225237** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 296 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Ramosetron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01225237
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01225237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01225237, "A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01225237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*